CardioFocus said today that it pulled in another $55 million for the HeartLight catheters it developed to treat atrial fibrillation.
Marlborough, Mass.-based CardioFocus said the round included its existing group of backers and included senior debt financing from Kennedy Lewis Investment Management. The proceeds are earmarked for commercializing its original HeartLight catheter and for the global launch of its HeartLight X3 device.
“This substantial investment will enable broader adoption of the HeartLight system and support a successful commercial launch of the HeartLight X3 system globally,” chairman Paul LaViolette said in prepared remarks. “We are committed to continued innovation and are very excited about the potential the HeartLight X3 system has to significantly advance the way AFib is treated.”
The latest round takes the total raised by CardioFocus to $159 million, dating back to a $6 million debt offering in June 2009 and including $21 million raised nearly a year ago from a single investor.
In March the company won CE Mark approval in the European Union for the HeartLight X3, its third-generation device.